Sygnature’s new HTS system combines Titian Mosaic sample management technology with an automation platform from HiRes Biosolutions

Novel features include a unique pKa model, combining quantum mechanics and machine learning methods, and extended capabilities in structure-based design

Incorporating AI technologies that highlight the most confident, accurate compound predictions to enable effective project decision-making

Recent discovery provides a novel approach to developing new cancer immunotherapy medicines that can be administered as a pill, compared to existing intravenous therapeutics

Sygnature’s Computational Chemistry department have spent the past year looking at how augmented reality can be applied to drug discovery

Single crystal X-ray diffraction analysis of low-molecular-weight active pharmaceutical ingredient crystal structures requires a single crystal of 10 μm or more, making microcrystal analysis challenging

Experimental validation confirms the ability of artificial intelligence to accelerate drug discovery

Potential for new drug to prevent colorectal cancer tumors

Discovery may eventually lead to the development of new kinds of non-opioid pain relievers

Microfluidic tech effectively shrinks a medical pathology laboratory onto a small chip